• The Company
    • Who we are
    • Partner Portal
  • Meet the Partners
  • Our Approach
  • Portfolio
    • Current Portfolio
    • Historic Portfolio
  • News
  • Contact Us
The Vertical Group
Investing for Innovation

OncoMed to Present at Two Upcoming Investor Conferences in September

8/29/2018

 
Via: MarketWatch
OncoMed Pharmaceuticals, Inc. OMED, +6.44% a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that John Lewicki, Ph.D., President and Chief Executive Officer of OncoMed, will provide a corporate update at two upcoming investor conferences. 

  • Wells Fargo Securities 2018 Healthcare Conference in Boston, MA on September 5, 2018 at 9:40 am Eastern Time
  • 20 [th] Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC in New York, NY on September 6, 2018 at 4:40 pm Eastern Time

​To access the live webcasts and subsequent archived recordings of these and other company presentations, please visit OncoMed's website at www.oncomed.com/invest/events.cfm. A replay of each presentation will be available for 30 days following the date of the event.


Read More: https://www.marketwatch.com/press-release/oncomed-to-present-at-two-upcoming-investor-conferences-in-september-2018-08-29

Outset Medical Closes $132 Million Financing to Accelerate Launch of Tablo Hemodialysis System

8/28/2018

 
Via: Business Wire
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, a commercial-stage company delivering first-of-its-kind technology into the growing global dialysis market, today announced that it raised $132 million in a Series D equity financing. The round was led by new investor Mubadala Investment Company, Abu Dhabi’s leading investment company, active in numerous sectors and more than 30 countries around the world. Existing investors Baxter Ventures, the venture capital arm of Baxter International, Fidelity Management and Research Company, Partner Fund Management LP, Perceptive Advisors, funds advised by T. Rowe Price Associates Inc., and Warburg Pincus also participated in the equity round.

The company will use the proceeds from the financing to increase production capabilities and accelerate commercial expansion of its Tablo®Hemodialysis System in acute and chronic care markets in the United States. Designed to reduce the cost and complexity of dialysis, Tablo expands how, when, and where dialysis can be provided.

Read More: 
https://www.businesswire.com/news/home/20180828005589/en/Outset-Medical-Closes-132-Million-Financing-Accelerate

WVU Heart and Vascular Institute offering new procedure for carotid artery disease

8/15/2018

 
Via: WVU Medicine
MORGANTOWN, W.Va. – Surgeons at the WVU Heart and Vascular Institute are now offering a new minimally invasive treatment for patients with carotid artery disease.

The carotid arteries are the two large blood vessels in the neck that supply the brain and head with blood. Carotid artery disease occurs when the arteries become narrow or blocked as the result of a buildup of fatty plaque. This can cause small clots to form, and those clots can cause a stroke.

Currently, the most common treatments for severe carotid artery disease are carotid endarterectomy, an open surgical procedure, and transfemoral carotid angioplasty and stenting, a minimally invasive option for patients at high risk for stroke and other complications.

Surgeons at the WVU Heart and Vascular Institute are now performing transcarotid artery revascularization (TCAR) using the ENROUTE® Transcarotid Neuroprotection System, which is designed to reduce the risk of stroke while inserting the ENROUTE® Transcarotid Stent. 

Read More: 
https://wvumedicine.org/news/article/wvu-heart-and-vascular-institute-offering-new-procedure-for-carotid-artery-disease/

TCAR (Transcarotid Artery Revascularization): The Next Step in the Evolution of Carotid Revascularization

8/1/2018

 
Via: Endovascular Today
Since its introduction in the 1950s, carotid endarterectomy (CEA) has been considered the gold standard treatment option for carotid revascularization. However, in patients with high-risk anatomic and/or physiologic characteristics, CEA is associated with higher rates of adverse outcomes.1 Transfemoral carotid angioplasty and stenting (TF-CAS) was introduced over 2 decades ago as a potential alternative. However, its effectiveness compared to CEA remains unclear, and full adoption of TF-CAS has been hindered by a higher rate of periprocedural stroke.2

Transcarotid artery revascularization (TCAR) was first introduced in the United States in 2012. TCAR is a surgically inspired procedure based upon concepts developed by vascular surgeons Enrique Criado, MD, and David Chang, MD. The technique combines direct carotid artery access and robust reversal of flow during transcarotid stent placement to provide CEA-like neuroprotection in a less-invasive approach.3

Read More: https://evtoday.com/2018/08/supplement/tcar-transcarotid-artery-revascularization-the-next-step-in-the-evolution-of-carotid-revascularization/

    Archives

    December 2020
    November 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    December 2019
    November 2019
    October 2019
    August 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    April 2015
    March 2015
    February 2015
    January 2015
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    February 2014
    January 2014
    December 2013
    October 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013

    RSS Feed

© The Vertical Group - info@vertical-group.com
 PO 218, Berkeley Heights, NJ 07922 | (908) 277-3737
PO 5006, San Mateo, CA  94402 | (650) 566-9060
Picture
Website by Custom Dynamics